Stoke Therapeutics Inc [STOK] stock is trading at $12.36, down -1.12%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The STOK shares have gain 2.57% over the last week, with a monthly amount glided 1.39%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, TD Cowen upgraded its rating to Outperform on March 26, 2024. TD Cowen downgraded its rating to a Market Perform. BofA Securities upgraded its rating to a Neutral and raised its price target to $12 on May 01, 2023. In a note dated January 06, 2023, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $22 to $9.
Stoke Therapeutics Inc [STOK] stock has fluctuated between $3.46 and $17.58 over the past year. Currently, Wall Street analysts expect the stock to reach $30.6 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $12.36 at the most recent close of the market. An investor can expect a potential return of 147.57% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 15.16M for the trailing twelve months, which represents a growth of 294.72%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -7.56%, Pretax Profit Margin comes in at -6.83%, and Net Profit Margin reading is -6.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.58 and Total Capital is -0.44. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 12.27 points at the first support level, and at 12.17 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.45, and for the 2nd resistance point, it is at 12.53.
Ratios To Look Out For
For context, Stoke Therapeutics Inc’s Current Ratio is 6.67. As well, the Quick Ratio is 6.67, while the Cash Ratio is 4.35. Considering the valuation of this stock, the price to sales ratio is 42.92, the price to book ratio is 2.66.
Transactions by insiders
Recent insider trading involved Ticho Barry, CHIEF MEDICAL OFFICER, that happened on Oct 01 ’24 when 10000.0 shares were sold. 10% Owner, Skorpios Trust completed a deal on Sep 19 ’24 to sell 1.94 million shares. Meanwhile, Affiliate Blue Horizon E LTD bought 1.94 million shares on Sep 19 ’24.
